Wealth Architects’s Aridis Pharmaceuticals Inc. Common Stock ARDS Stock Holding History

Wealth Architects’s Portfolio ARDS Stock Details ARDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-14,077	Closed	-$1.44K	–	205
2023 Q3	$1.44K	Hold	14,077	–	–	﹤0.01%	188
2023 Q2	$3.1K	Hold	14,077	–	–	﹤0.01%	193
2023 Q1	$4.42K	Hold	14,077	–	–	﹤0.01%	189
2022 Q4	$16.6K	Hold	14,077	–	–	﹤0.01%	179
2022 Q3	$13K	Hold	14,077	–	–	﹤0.01%	173
2022 Q2	$15K	Hold	14,077	–	–	﹤0.01%	182
2022 Q1	$25K	Hold	14,077	–	–	﹤0.01%	206
2021 Q4	$33K	Hold	14,077	–	–	0.01%	199
2021 Q3	$52K	Buy	+14,077	New	+$65K	0.01%	181

Other funds holding ARDS

BCWM

Bartlett & Co Wealth Management Cincinnati, Ohio $7.82B AUM 15.4% 1-Year Est. Return

Wealth Architects's ARDS Position: Q4 2023 in Review

Wealth Architects sold out of Aridis Pharmaceuticals Inc. Common Stock (ARDS) in Q4 2023, closing a stake of 14,077 shares — an estimated $1.44K sold.

Wealth Architects first reported a position in ARDS in Q3 2021 and held it in 9 quarters. The position peaked at $52K in Q3 2021. 2 funds tracked by Wall St. Rank hold ARDS as of Q4 2023.

Wealth Architects reported no remaining Aridis Pharmaceuticals Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Wealth Architects sold 14,077 Aridis Pharmaceuticals Inc. Common Stock shares in Q4 2023, an estimated $1.44K.
Wealth Architects first reported a position in Aridis Pharmaceuticals Inc. Common Stock in Q3 2021 and held it in 9 quarters.
Wealth Architects's Aridis Pharmaceuticals Inc. Common Stock position peaked at $52K in Q3 2021.
2 funds tracked by Wall St. Rank held Aridis Pharmaceuticals Inc. Common Stock as of Q4 2023.

Based on Wealth Architects's 13F filing for Q4 2023, filed 14 Feb 2024.